Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients

Blood

Volumn 118, Issue 16, 2011, Pages 4346-4352

  Cibeira, Maria Teresa ^a,b,c   Sanchorawala, Vaishali ^a,b   Seldin, David C ^a,b   Quillen, Karen ^a,b   Berk, John L ^a   Dember, Laura M ^a   Segal, Adam ^a   Ruberg, Frederick ^a   Meier Ewert, Hans ^a   Andrea, Nancy T ^b   Sloan, J Mark ^a,b   Finn, Kathleen T ^a,b   Doros, Gheorghe ^d   Blade, Joan ^c   Skinner, Martha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; AL AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80054844341     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-330738     Document Type: Article

References (34)

1. Kyle RA, LinosA, Beard CM, et al. Incidence and natural history of primary systemic amiloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-1822.
2. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine vs colchicine only. Am J Med. 1996; 100(3):290-298. (Pubitemid 26111626)
3. Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93(3):1062-1066. (Pubitemid 29067872)
4. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med. 1997;336(17):1202-1207. (Pubitemid 27183649)
5. Gertz MA, Lacy MQ, Lust JA, et al. Prospective randomized trial of melphalan and prednisone vs vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. 1999; 17(1):262-267. (Pubitemid 29022401)
6. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276-4282. (Pubitemid 34627192)
7. Moureau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101(4): 766-769. (Pubitemid 28308529)
8. Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant. 2004; 33(3):271-277. (Pubitemid 38256558)
9. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140(2):85-93.
10. Gertz MA, Blood E, Vesole DH, et al. A multi-center phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant. 2004; 34(2):149-154. (Pubitemid 39077106)
11. Schonland SO, Perz JB, Hundemer M, et al. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation. 2005;80(1 suppl):S160-S163. (Pubitemid 41552930)
12. Chow LQ, Bahlis N, Russell J, et al. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant. 2005;36(7):591-596. (Pubitemid 43115013)
13. Goodman HJ, Gillmore JD, Lachmann HJ, et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol. 2006;134(4):417-425. (Pubitemid 44079555)
14. Vesole DH, Perez WS, Akasheh M, et al. Highdose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc. 2006;81(7):880-888. (Pubitemid 43993479)
15. Gertz MA, Lacy MQ, Dispenzieeri A, et al. Transplantation for amyloidosis. Curr Opin Oncol. 2007;19(2):136-141. (Pubitemid 46204353)
16. Sanchorawala V, Seldin DC. An overview of highdose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid. 2007; 14(4):261-269. (Pubitemid 350035577)
17. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103(10): 3960-3963. (Pubitemid 38596319)
18. Perfetti V, Siena S, Palladini G, et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica. 2006;91(12):1635-1643. (Pubitemid 46032961)
19. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561-3563. (Pubitemid 350159622)
20. Dember LM, Sanchorawala V, Seldin DC. Effect of dose intensive intravenous melphalan and autologus blood stem cell transplantation on an AL amyloidosis-associated renal disease. Ann Intern Med. 2001;134(9):746-753. (Pubitemid 32402067)
21. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92(10):1415- 1418. (Pubitemid 350144161)
22. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51(12):2181-2187.
23. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4):319-328. (Pubitemid 41098849)
24. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
25. Peto R, Pike MC. Conservation of the approximation of (O-E)2/E in the log-rank test for survival data on tumour incidence rate. Biometrics. 1973; 29(3):579-584.
26. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011;46(7):970-975.
27. Bladé J, Vesole DH, Gertz M. High-dose therapy in multiple myeloma. Blood. 2003;102(10):3469-3470.
28. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 2010;115(18):3655-3663.
29. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78-84. (Pubitemid 36819341)
30. Jaccard A, Moreau P, Leblond V, et al. Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup: high-dose melphalan vs melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-1093.
31. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787-788. (Pubitemid 47105419)
32. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
33. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
34. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-1933.